The early-stage drug discovery company with operations in Oxford and Boston is looking to increase its drug discovery and validation capabilities in key neuro disease areas.
The funding will help to develop a unique solution that will enhance the effect of post-surgical radiotherapy on aggressive brain tumours and reduce the chance of cancer regrowth.
The funding, over the next five years, was awarded to Oxford’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).
The study analysed samples from 300 patients with non-specific but concerning symptoms of cancer, and their results show that cancer was correctly detected in 19 out of every 20 patients with cancer using this test.
The researchers believe their work could help compress vaccine development timelines to 100 days from pathogen identification to mass production and distribution.
The research, by scientists at the Rosalind Franklin Institute, has shown that nanobodies generated by llamas and camels can effectively target the SARS-CoV-2 virus that causes COVID-19.
The funding will allow The Oxford Trust to commence the conversion of dedicated high spec laboratory facilities with 3,000 sq ft of laboratory and close to 9,000 sq ft of allied space.
The study concludes that there are increased risks of some haematological and vascular adverse events following vaccination, but the risks are substantially higher following a coronavirus infection.
Led by Blue Venture Fund, the new funding will accelerate Oxford-based Ultromics’ use of AI-enabled echocardiograms to improve patient outcomes.
The funding round included existing investors RA Capital Management, Oxford Sciences Innovation (OSI) and CureDuchenne Ventures and a host of new investors.
The expansion will see the firm occupy 20,151sq ft of laboratory and office space at 155 Brook Drive, which is part of the Science Vale Enterprise Zone.
The company, which initially occupied c7,800 sq ft in the Schrödinger Building is increasing capacity for its technology teams by expanding to 21,000 sq ft of facilities.